Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.47 |
| ▸ | SLC6A12 | P48065 | 5/20 | 0.45 |
| ▸ | SLC6A11 | P48066 | 5/20 | 0.45 |
| ▸ | SLC6A13 | Q9NSD5 | 5/20 | 0.45 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17429993 | 1.00 | ANPEP (0.47) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL939588 | 1.00 | ANPEP (0.47) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL10952451 | 0.93 | ANPEP (0.43) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL10952455 | 0.93 | ANPEP (0.43) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL10851234 | 0.93 | ANPEP (0.43) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL11798174 | 0.91 | ANPEP (0.42) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL24197646 | 0.87 | ANPEP (0.56) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL24483431 | 0.87 | ANPEP (0.56) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL74792 | 0.87 | — | — | |
| SCHEMBL431287 | 0.87 | ANPEP (0.56) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109957146-B | Preparation method of modified alumina particles used as nucleating agent | 中国石油天然气股份有限公司 | 2021-01-29 | — | — | CN | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| EP-4709710-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4587433-A1 | 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Takeda Pharmaceutical Company Limited (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-20250066331-A1 | ANTIFIBROTIC COMPOUNDS AND RELATED METHODS | UNIV FLORIDA STATE RES FOUND (US) | 2025-02-27 | — | — | US | disclosed |
| US-12180188-B2 | Antifibrotic compounds and related methods | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240391870-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| US-4329296-A | Branched chain and cycloaliphatic esters of the androstane and oestrane series and pharmaceutical compositions containing same | AKZONA INCORPORATED (US) | 1982-05-11 | — | — | US | disclosed |
| US-4312864-A | ANDROGENIC, ANABOLIC, ESTROGENIC, ANTIESTROGENIC | AKZONA INCORPORATED (US) | 1982-01-26 | — | — | US | disclosed |
| US-4307086-A | ANTIESTROGENS | AKZONA INCORPORATED (US) | 1981-12-22 | — | — | US | disclosed |
| US-4307087-A | ANTIESTROGENS | AKZONA INCORPORATED (US) | 1981-12-22 | — | — | US | disclosed |
| US-4212864-A | ANDROGENIC, ANABOLIC, ESTROGENIC AND ANTI-ESTROGENIC PROPERTIES | AKZONA INCORPORATED (US) | 1980-07-15 | — | — | US | disclosed |
| US-3936462-A | CNS DEPRESSANT, ANALGESIC | STERLING DRUG INC. (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391870-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | NSUN3, POLRMT, NPC1L1 | ANPEP 1666/4885ENPEP 2042/4885SLC6A12 385/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | ANPEP 3412/4885ENPEP 3288/4885SLC6A12 528/4885 |
| US-12180188-B2 | Antifibrotic compounds and related methods | COL1A1, COL2A1, COLGALT1 | ANPEP 1627/4885ENPEP 427/4885SLC6A12 4597/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | ANPEP 1480/4885ENPEP 3973/4885SLC6A12 3293/4885 |
| US-20250066331-A1 | ANTIFIBROTIC COMPOUNDS AND RELATED METHODS | COL1A1, COL2A1, COLGALT1 | ANPEP 1627/4885ENPEP 427/4885SLC6A12 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.